Gennao Bio

company

About

Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$1M
Industries
Biotechnology,Health Care,Life Science,Medical
Founded date
Jan 1, 2020
Number Of Employee
1 - 10
Operating Status
Active

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1M
Gennao Bio has raised a total of $1M in funding over 2 rounds. Their latest funding was raised on Dec 22, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 22, 2021 Series A $1M 1 CureDuchenne Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Gennao Bio is funded by 1 investors. CureDuchenne Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
CureDuchenne Ventures Yes Series A